Mucosal protection by phosphatidylcholine

Digestive Diseases

Volumn 30, Issue SUPPL. 3, 2012, Pages 85-91

  Stremmel, Wolfgang ^a   Ehehalt, Robert ^a   Staffer, Sabine ^a   Stoffels, Sabine ^a   Mohr, Andrea ^a   Karner, Max ^a   Braun, Annika ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Mucus; Phosphatidylcholine; Ulcerative colitis

Indexed keywords

EUDRAGIT; GASTROINTESTINAL AGENT; PHOSPHATIDYLCHOLINE; PLACEBO; RECOMBINANT PHOSPHATIDYLCHOLINE; SPHINGOMYELIN; STEROID; UNCLASSIFIED DRUG;

ARTICLE; BLOATING; CLINICAL FEATURE; DRUG DELIVERY SYSTEM; DRUG MECHANISM; HUMAN; HYDROPHOBICITY; ILEUM MUCOSA; INTESTINE MUCOSA; NAUSEA; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN SECRETION; TREATMENT RESPONSE; ULCERATIVE COLITIS;

EID: 84872079719     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000342729     Document Type: Article

References (41)

1. Fiochi C: Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998;115:182-205.
2. Podolsky D: Inflammatory bowel disease. N Engl J Med 2002;347:417-429. (Pubitemid 34851835)
3. Rath HC, Schultz M, Freitag R, Dieleman LA, Li F, Linde HJ, Schölmerich J, Sartor RB: Different subsets of enteric bacteria induce and perpetuate experimental colitis in rats and mice. Infect Immun 2001;69:2277-2285. (Pubitemid 32241818)
4. Backhed F, Ley RE, Sonnenburg JL, Peterson DA, Gordon JI: Host-bacterial mutualism in the human intestine. Science 2005;307:1915-1920. (Pubitemid 40404694)
5. Kubler I, Koslowski MJ, Gersemann M, Fellermann K, Beisner J, Becker S, Rothfuss K, Herrlinger KR, Stange EF, Wehkamp J: Influence of standard treatment on ileal and colonic antimicrobial defensin expression in active Crohn's disease. Aliment Pharmacol Ther 2009;30:621-633.
6. Becker T, Loch G, Beyer M, Zinke I, Aschenbrenner AC, Carrera P, Inhester T, Schultze J, Hoch M: FOXO-dependent regulation of innate immune homeostasis. Nature 2010;463:369-373.
7. Atuma C, Strugala V, Allen A, Holm L: The adherent gastrointestinal mucus gel layer: thickness and physical state in vivo. Am J Physiol Gastrointest Liver Physiol 2001;280:G922-G929.
8. Shirazi T, Longman RJ, Corfield AP, Probert CSJ: Mucins and inflammatory bowel disease. Postgrad Med J 2000;76:473-478. (Pubitemid 30639056)
9. Lamont JT: Mucus: the front line of intestinal mucosal defense. Ann N Y Acad Sci 1992;664:190-201. (Pubitemid 23022849)
10. Johannson MEV, Phillipson M, Petersson J, Velcich A, Holm L, Hansson GC: The inner of the two Muc2 mucin-dependent mucus layers in colon is devoid of bacteria. Proc Natl Acad Sci USA 2008;105:15064-15069.
11. Matsuo K, Ota H, Akamatsu T, Sugiyama A, Katsuyama T: Histochemistry of the surface mucous gel layer of the human colon. Gut 1997;40:782-790.
12. DeSchryver-Kecskemeti K, Eliakim R, Carroll S, Stenson WF, Moxley MA, Alpers DH: Intestinal surfactant-like material. A novel secretory product of the rat enterocyte. J Clin Invest 1989;84:1355-1361. (Pubitemid 19247612)
13. Butler BD, Lichtenberger LM, Hills BA: Distribution of surfactants in the canine gastrointestinal tract and their ability to lubricate. Am J Physiol 1983;244:G645-G651. (Pubitemid 13065759)
14. Hicks AM, DeLong CJ, Thomas MJ, Samuel M, Cui Z: Unique molecular signatures of glycerophospholipid species in different rat tissues analyzed by tandem mass spectrometry. Biochim Biophys Acta 2006;1761:1022-1029. (Pubitemid 44354286)
15. Hills BA: Surface-active phospholipid: a Pandora's box of clinical applications. Part II. Barrier and lubricating properties. Intern Med J 2002;32:242-251.
16. Lichtenberger LM: The hydrophobic barrier properties of gastrointestinal mucus. Annu Rev Physiol 1995;57:565-583. Review.
17. Willumeit R, Schuster A, Iliev P, Linser S, Feyerabend F: Phospholipids as implant coatings. J Mater Sci Mater Med 2007;18:367-380. (Pubitemid 46332861)
18. Guo W, Andersson R, Odselius R, Ljungh A, Wadström T, Bengmark S: Phospholipid impregnation of abdominal rubber drains: resistance to bacterial adherence but no effect on drain-induced bacterial translocation. Res Exp Med 1993;193:285-296. (Pubitemid 23319583)
19. Ehehalt R, Jochims C, Lehmann WD, Erben G, Staffer S, Reininger C, Stremmel W: Evidence of luminal phosphatidylcholine secretion in rat ileum. Biochim Biophys Acta 2004;1682:63-71. (Pubitemid 38670536)
20. Alpers DH, Zhang Y, Ahnen DJ: Synthesis and parallel secretion of rat intestinal alkaline phosphatase and a surfactant-like particle protein. Am J Physiol 1995;268:E1205-E1214.
21. Engle MJ, Grove ML, Becich MJ, Mahmood A, Alpers DH: Appearance of surfactant-like particles in apical medium of Caco-2 cells may occur via tight junctions. Am J Physiol 1995;268:C1401-C1413.
22. Ehehalt R, Wagenblast J, Erben G, Lehmann WD, Hinz U, Merle U, Stremmel W: Phosphatidylcholine and lysophosphatidylcholine in intestinal mucus of ulcerative colitis patients. A quantitative approach by nano-Electrospray-tandem mass spectrometry. Scand J Gastroenterol 2004;39:737-742. (Pubitemid 39093247)
23. Braun A, Treede I, Gotthardt D, Tietje A, Zahn A, Ruhwald R, Schoenfeld U, Welsch T, Kienle P, Erben G, Lehmann WD, Fuellekrug J, Stremmel W, Ehehalt R: Alterations of phospholipid concentration and species composition of the intestinal mucus barrier in ulcerative colitis: a clue to pathogenesis. Inflamm Bowel Dis 2009;15:1705-1720.
24. Braun A, Schoenfeld U, Welsch T, Kadmon M, Funke B, Gotthardt D, Zahn A, Autschbach F, Kienle P, Zharnikov M, Grunze M, Stremmel W, Ehehalt R: Reduced hydrophobicity of the colonic mucosal surface in ulcerative colitis as a hint at a physicochemical barrier defect. Int J Colorectal Dis 2011;26:898-998.
25. Meves A, Stremmel C, Gottschalk K, Fässler R: The kindling protein family: new members to the club of focal adhesion proteins. Trends Cell Biol 2009;19:504-512.
26. Ussar S, Moser M, Widmaier M, Rognoni E, Harrer C, Genzel-Boroviczeny O, Fässler R: Loss of Kindlin-1 causes skin atrophy and lethal neonatal intestinal epithelial dysfunction. PLoS Genet 2008;4:e1000289.
27. Karner M, Ehehalt R, Stremmel W: Retarded release phosphatidylcholine: A new therapeutic option for ulcerative colitis; in A. Dignass, D. Rachmilewitz, E. F. Stange, J. V. Weinstock (eds): Immunoregulation in Inflammatory Bowel Diseases - Current Understanding and Innovation. Heidelberg, Springer, 2007, pp 161-170.
28. Gibson PR, Muir JG: Reinforcing the mucus: a new therapeutic approach for ulcerative colitis? Gut 2005;54:900-903. (Pubitemid 40873897)
29. Nazareth M, Mahadevan U: Phosphatidylcholine in steroid refractory chronic ulcerative colitis - is it all in the mucus? Ann Intern Med 2007;147:603-610.
30. Anes E, Kühnel MP, Bos E, Moniz-Pereira J, Habermann A, Griffiths G: Selected lipids activate phagosome actin assembly and maturation resulting in killing of pathogenic mycobacteria. Nat Cell Biol 2003;5:793-802. (Pubitemid 37087167)
31. Treede I, Braun A, Jeliaskova P, Giese T, Füllekrug J, Griffiths G, Stremmel W, Ehehalt R: TNF-alpha-induced up-regulation of proinflammatory cytokines is reduced by phosphatidylcholine in intestinal epithelial cells. BMC Gastroenterol 2009;9:53.
32. Gutierrez MG, Gonzalez AP, Anes E, Griffiths G: Role of lipids in killing mycobacteria by macrophages: evidence for NFkappaB-dependent and -independent killing induced by different lipids. Cell Microbiol 2009;11:406-420.
33. Are AF, Galkin VE, Pospelova TV, Pinaev GP: The p65/RelA subunit of NF-kappaB interacts with actin-containing structures. Exp Cell Res 2000;256:533-544. (Pubitemid 30244211)
34. Stremmel W, Merle U, Zahn A, Autschbach F, Hinz U, Ehehalt R: Retarded release phosphatidylcholine benefits patients with chronic active ulcerative colitis. Gut 2005;54:966-971. (Pubitemid 40873911)
35. Stremmel W, Braun A, Hanemann A, Ehehalt R, Autschbach F, Karner M: Delayed release phosphatidylcholine in chronic-active ulcerative colitis: a randomized, doubleblinded, dose finding study. J Clin Gastroenterol 2010;44:e101-e107.
36. Stremmel W, Ehehalt R, Autschbach F, Karner M: Efficacy of retarded release phosphatidylcholine for treatment of chronic, steroid refractory ulcerative colitis. Ann Intern Med 2007;147:603-610.
37. Ogasawara N, Kojima T, Go M, Ohkuni T, Koizumi JI, Kamekura R, Masaki T, Murata M, Tanaka S, Fuchimoto J, Himi T, Sawada N: PPARgamma agonists upregulate the barrier function of tight junctions via a PKC pathway in human nasal epithelial cells. Pharmacol Res 2010;61:489-498.
38. Best G, Amberger R, Baddeley D, Ach T, Dithmar S, Heintzmann R, Cremer C: Structured illumination microscopy of autofluorescent aggregations in human tissue. Micron 2011;42:330-335.
39. Elsing C, Winn-Börner U, Stremmel W: Confocal analysis of hepatocellular longchain fatty acid uptake. Am J Physiol 1995;269:G842-G851.
40. Gotthardt D, Blancheteau V, Bosserhoff A, Ruppert T, Delorenzi M, Soldati T: Proteomics fingerprinting of phagosome maturation and evidence for the role of a Galpha during uptake. Mol Cell Proteomics 2006;5:2228-2243. (Pubitemid 46040630)
41. Reinhard L, Rupp C, Riedel HD, Ruppert T, Giese T, Flechtenmacher C, Weiss KH, Kloeters-Plachky P, Stremmel W, Schirmacher P, Sauer P, Gotthardt DN: S100A9 is a biliary protein marker of disease activity in primary sclerosing cholangitis. PLoS One 2012;7:e29821.